| Zou, Zhangyu |
NCT06298552: A Phase 3 Study to Evaluate the Efficacy and Safety of Efgartigimod IV in Patients with Acetylcholine Receptor Binding Antibody Seronegative Generalized Myasthenia Gravis |
|
|
| Recruiting | 3 | 110 | Europe, Canada, US, RoW | Efgartigimod IV, Placebo IV | argenx | Generalized Myasthenia Gravis | 07/25 | 07/27 | | |
NIMBLE, NCT05070858 / 2020-003272-41: A Study to Test How Safe Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Alone Are and How Well They Work in Adult Patients With Generalized Myasthenia Gravis |
|
|
| Recruiting | 3 | 235 | Europe, Canada, Japan, US, RoW | Pozelimab + Cemdisiran, Cemdisiran, ALN-CC5, Placebo, Pozelimab, REGN3918 | Regeneron Pharmaceuticals | Generalized Myasthenia Gravis | 05/25 | 03/28 | | |
| Zhao, Yuanqi |
NCT06298552: A Phase 3 Study to Evaluate the Efficacy and Safety of Efgartigimod IV in Patients with Acetylcholine Receptor Binding Antibody Seronegative Generalized Myasthenia Gravis |
|
|
| Recruiting | 3 | 110 | Europe, Canada, US, RoW | Efgartigimod IV, Placebo IV | argenx | Generalized Myasthenia Gravis | 07/25 | 07/27 | | |
NIMBLE, NCT05070858 / 2020-003272-41: A Study to Test How Safe Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Alone Are and How Well They Work in Adult Patients With Generalized Myasthenia Gravis |
|
|
| Recruiting | 3 | 235 | Europe, Canada, Japan, US, RoW | Pozelimab + Cemdisiran, Cemdisiran, ALN-CC5, Placebo, Pozelimab, REGN3918 | Regeneron Pharmaceuticals | Generalized Myasthenia Gravis | 05/25 | 03/28 | | |
FASTAR, NCT04261764: Fasting-mimicking Diet Combined With Traditional Chinese Medicine for Phlegm-dampness Type Obesity Patients |
|
|
| Recruiting | N/A | 40 | RoW | Fastening-mimicking diet combined with a "dispelling dampness" meal replacement, Normal diet | Guangdong Provincial Hospital of Traditional Chinese Medicine | Obesity | 11/21 | 02/22 | | |
| Jiang, Haishan |
NCT05092841: A Study to Assess the Efficacy and Safety of PXT3003 in Charcot-Marie-Tooth Type 1A |
|
|
| Completed | 3 | 176 | RoW | PXT3003, (RS)-baclofen, naltrexone hydrochloride and D-sorbitol oral fixed dose combination, PXT3003 placebo, liquid oral solution | Tasly GeneNet Pharmaceuticals Co., Ltd | Charcot-Marie-Tooth Type 1A | 03/24 | 03/24 | | |
NIMBLE, NCT05070858 / 2020-003272-41: A Study to Test How Safe Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Alone Are and How Well They Work in Adult Patients With Generalized Myasthenia Gravis |
|
|
| Recruiting | 3 | 235 | Europe, Canada, Japan, US, RoW | Pozelimab + Cemdisiran, Cemdisiran, ALN-CC5, Placebo, Pozelimab, REGN3918 | Regeneron Pharmaceuticals | Generalized Myasthenia Gravis | 05/25 | 03/28 | | |
| Recruiting | 2/3 | 104 | RoW | B007, Placebo | Shanghai Jiaolian Drug Research and Development Co., Ltd, Shanghai Pharmaceuticals Holding Co., Ltd | Generalized Myasthenia Gravis | 06/26 | 06/26 | | |
| Zeng, Wenshuang |
NIMBLE, NCT05070858 / 2020-003272-41: A Study to Test How Safe Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Alone Are and How Well They Work in Adult Patients With Generalized Myasthenia Gravis |
|
|
| Recruiting | 3 | 235 | Europe, Canada, Japan, US, RoW | Pozelimab + Cemdisiran, Cemdisiran, ALN-CC5, Placebo, Pozelimab, REGN3918 | Regeneron Pharmaceuticals | Generalized Myasthenia Gravis | 05/25 | 03/28 | | |
